Difference between revisions of "Team:Austin UTexas/Results"

Line 296: Line 296:
 
<br>
 
<br>
  
<p style="font-family: verdana"><i> Lactobacillus plantarum </i> is a gram-positive lactic acid producing bacteria, so it requires a different growth media than we typically use in our lab. In 1954, Briggs agar was developed (9). This media was designed for <i>Lactobacilli</i>, but was not sufficient for many species, including <i> Lactobacillus plantarum </i>, so a different non-selective media for general <i>Lactobacilli</i> was developed in 1960 by Man, Rogosa and Sharpe and named MRS (10). We have exclusively grown our <i> Lactobacillus plantarum </i> on MRS media. Further, we grew <i> Lactobacillus plantarum </i> in a CO2 incubator as referenced in most literature we studied (11-13). The metabolic pathways in the bacteria alter when grown aerobically to produce excess acetate (14) and less lactic acid. Because we intend to utilize this bacteria in a fermentable food, a change in this metabolic pathway would not benefit our ultimate goal.</p>
+
<p style="font-family: verdana"><i> Lactobacillus plantarum </i> is a gram-positive lactic acid producing bacteria, so it requires a different growth media than we typically use in our lab. In 1954, Briggs agar was developed (9). This media was designed for <i>Lactobacilli</i>, but was not sufficient for many species, including <i> Lactobacillus plantarum </i>, so a different non-selective media for general <i>Lactobacilli</i> was developed in 1960 by Man, Rogosa and Sharpe and named MRS (10). We have exclusively grown our <i> Lactobacillus plantarum </i> on MRS media. Further, we grew <i> Lactobacillus plantarum </i> in a CO2 incubator as referenced in most literature we studied (11-13). The metabolic pathways in the bacteria alter when grown aerobically to produce excess acetate (14) and less lactic acid. Because we intend to utilize this bacteria in a fermentable food, a change in this metabolic pathway would not benefit our ultimate goal.<a href="https://2017.igem.org/Team:Austin_UTexas/Protocols">Click here for our MRS media recipe</a></p>
  
<br>
 
 
<a href="https://2017.igem.org/Team:Austin_UTexas/Protocols">Click here for our electroporation protocol</a>
 
 
<button class="accordion">MRS Media</button>
 
<div class="panel">
 
 
<br>
 
 
  <ul style="font-family: verdana">
 
  <li>MRS broth was prepared using 55g of Difco MRS broth powder in 1L of distilled water. The solution was then autoclaved and stored in a 4&#8451 C refrigerator along with the Difco MRS powder.</li>
 
  <li>MRS agar was prepared by mixing 55g of Difco MRS broth powder and 15g of agar flakes in 1 L of water. The solution was then autoclaved and stored in a 4 degree refrigerator along with the Difco MRS powder.</li>
 
</div>
 
  
 
<br>
 
<br>
Line 318: Line 305:
 
<br>
 
<br>
  
<p style="font-family: verdana">The Texas Tech iGEM team helped us by testing the Speer protocol after we had attempted three procedures and hadn't successfully transformed. They were not able to successfully transform using the Speer protocol which suggests that the procedure was either too simplified for researchers who have never transformed gram-positive bacteria, or was not compatible with <i>Lactobacillus plantarum.</i>
+
<p style="font-family: verdana">The Texas Tech iGEM team helped us by testing the Speer protocol after we had attempted three procedures and hadn't successfully transformed. They were not able to successfully transform using the Speer protocol which suggests that the procedure was either too simplified for researchers who have never transformed gram-positive bacteria, or was not compatible with <i>Lactobacillus plantarum.</i><a href="https://2017.igem.org/Team:Austin_UTexas/Protocols">Click here for our electroporation protocol</a></p>
  
<a href="https://2017.igem.org/Team:Austin_UTexas/Protocols">Click here for our electroporation protocol</a>
 
 
<button class="accordion">Electroporation of <i>L. plantarum</i></button>
 
<div class="panel">
 
 
  <br>
 
 
  <h4 style="font-family: verdana">Materials Needed</h4>
 
 
<br>
 
 
  <ul>
 
  <li>MRS liquid media</li>
 
  <li>L. plantarum cells</li>
 
  <li>Glass culture tube</li>
 
  <li>CO2 incubator</li>
 
  <li>MRS liquid media, containing 0.5 M sucrose</li>
 
  <li>Spectrophotometer</li>
 
  <li>Centrifuge</li>
 
  <li>Vortex</li>
 
  <li>50 mL Falcon conical tubes (2)</li>
 
  <li>30% PEG 8000</li>
 
  </ul>
 
 
  <br>
 
 
  <h4>Preparation of Recipient Cell Stocks</h4>
 
 
<br>
 
 
  <ol style="font-family: verdana">
 
  <li>Inoculate 10-25 mL of -80 &#2103 L. Plantarum stocks in MRS broth at 37 &#2103 CO2 incubator, overnight without shaking.</li>
 
  <li>Subculture by incubating culture in a 200 mL of prewarmed MRS broth. Add culture until OD600 is 0.1.</li>
 
  <li>Subcultures should be grown to an OD600 of 0.6 (4-8 hours).</li>
 
  <li>For glycine supplementation, the MRS broth should contain 0.5%-1.0% glycine.</li>
 
  <li>For NaCl supplementation, inoculate subcultures with 0.9M of NaCl.</li>
 
  <li>Harvest cells from the subculture by centrifugation at 4 &#2103 for 10 min. at 7000 rpm after inoculation.</li>
 
  <li>Rinse the cells in 200 mL of sterile, distilled water (~4 &#2103) and centrifuge again.</li>
 
  <li>Resuspend the pellet in 2-3 mL of cold, sterile, distilled water and aliquot 1 mL volumes to 1.5 mL microcentrifuge tubes.</li>
 
  <li>Centrifuge aliquots at 15,000 rpm for ~90 seconds and remove the supernatant.</li>
 
  <li>Rinse the cells twice with 1 mL of cold, distilled, sterile water. Then rinse with 1 mL of cold, sterile 30% PEG-8000 solution. Remove the supernatant.</li>
 
  <li>Suspend cells in 0.5-0.6 mL of 30% PEG for storage at -80 &#2103. These should retain viability for up to 2 years.</li>
 
  </ol>
 
<br>
 
  <h4>Treatment of Cells Prior to Electroporation</h4>
 
<br>
 
  <ol style="font-family: verdana">
 
  <li>Thaw on Ice.</li>
 
  <li>Suspend cells in  900μL of cold, sterile, distilled water for 30 min.</li>
 
  <li>Treat with 100mM lithium acetate and 10mM DTT solution for 30min.</li>
 
  <li>After pretreatment, the cells were pelleted for 2-3 minutes in a microcentrifuge, washed once in 1 mL of cold, sterile, 30% PEG solution and suspended in 0.5-0.6 mL cold, sterile PEG solution for electroporation.</li>
 
  </ol>
 
 
<br>
 
 
  <h4 style="font-family: verdana">Electroporation</h4>
 
  <ol style="font-family: verdana">
 
  <li>Isolate intended vector (<i>Lactobacillus plantarum</i> experiment as of 09/06/17 has been using pMSP3535).</li>
 
  <li>200 ng/transformation of plasmid DNA is mixed with 100μL of cell suspension and transferred to a prechilled electroporation cuvette with a 0.2 cm gap.</li>
 
  <li>Pulse at 12.5kV (From Literature: Bio-rad gene pulser with capacitance setting at 25μF and resistances of 200 or 400 Ω and voltage settings of 1500, 2000 or 2500 V (7.5, 10 or 12.5 kV cm-1).</li>
 
  <li>Quickly recover cells by adding 900μL of recovery medium (0.5 M sucrose in MRS broth) to the cuvette then transfer the cells to a sterile microcentrifuge tube for incubation ~4 hours at 37oC in a CO2 incubator without shaking. (*Save recovery and plate again if no growth)</li>
 
  <li>Dilute cells in recovery medium and plate on MRS agar along with the proper concentration of any antibiotics that the plasmid of choice has resistancy (pMSP3535 has resistance to erythromycin).</li>
 
  <li>Incubate plates for 2 days, then count the colonies present. Allow an additional 3-4 days after initial count to ensure all were noted.</li>
 
  <li>Cells stored in glycerol (-80 &#2103) after electroporation incubation can be expected to yield similar results to the cells that were plated directly after the incubation.</li>
 
  </ol>
 
 
<br>
 
  
</div>
 
  
 
<br>
 
<br>

Revision as of 16:13, 1 November 2017


Results

Although bacteria can naturally synthesize GABA, we wanted to increase expression of the gadB gene and subsequently GABA production in order to imbue our intended probiotic, Lactobacillus plantarum with a more potent medicinal quality, with the idea that this GABA-overproducing probiotic can then be consumed by patients with bowel disorders, hypternsion or anxiety (1). Overexpression of the gadB gene will be accomplished by placing it under the control of either the P8 or P32 constitutive promoters from Lactococcus lactis (2).

To make our GABA-producing probiotic, we ultimately needed to assemble a GABA overexpression cassette plasmid using the Golden Gate assembly method. The intention here is that bacteria containing this GABA overexpression cassette plasmid should produce high levels of GABA. In short, Golden Gate Assembly is a new cloning method that allows for the creation of a multi-part DNA assembly (i.e. cassette plasmid) in a single reaction through the use of DNA parts containing specific, predefined suffixes and prefixes with recognition sites for Type IIs restriction enzymes (e.g. BsmBI and BsaI). The specificity of these suffixes and prefixes provides directionality of the desired DNA parts during the assembly process. For our purposes, we used the MoClo Yeast Tool Kit developed by John Dueber (3).

We decided to first assemble and test our Golden Gate plasmids in E. coli, which was chosen due to the ease in which we could genetically manipulate it. We then wanted to use these Golden Gate plasmids to genetically manipulate L. platnarum. This part of the project required us to assemble a Golden Gate compatible shuttle vector (compatible in both E. coli and L. plantarum ) and transform L. plantarum. Our experimental results are detailed below.

Click on one of the images above to learn more about our results!



Golden Gate Compatible Shuttle Vector

We wanted to assemble our final GABA overexpression cassette plasmid using the shuttle vector pMSP3535 as the backbone (Fig. 9). To do this, we first needed to make pMSP3535 Golden Gate compatible (i.e. free of BsaI restriction sites and containing correct overhangs for cassette assembly). We chose to work with pMSP3535 as it contains both a ColE1 origin for replication in E. coli and a pAMb1 origin for replication in Gram-positive bacteria including Lactobacillus species (7), allowing us to easily transplant our cassette plasmid from E. coli to Lactobacillus plantarum once assembled. Additionally, the pMSP3535 vector contains the resistance gene for erythromycin, of which Lactobacillus plantarum is naturally susceptible (8).


Figure 9. Golden Gate assembly of the GABA final overexpression cassette plasmid with the Golden Gate compatible pMSP3535 vector and the P8/P32 promoter, gadB gene, and M13 terminator part plasmids.


The process of making the pMSP3535 vector Golden Gate compatible involved two steps: 1) assembling the pMSP3535 backbone (pAMb1 origin and erythromycin resistance gene) with a new ColE1 origin; 2) assembling a gfp dropout part to the assembly of the pMSP3535 backbone and the new ColE1 origin (Fig. 10).


Figure 10. Assembly workflow for creating the Golden Gate compatible pMSP3535 backbone. The first step involves replacing the ColE1 origin in the pMSP3535 backbone with a new ColE1 origin from pYTK001 to create a pMSP3535 + ColE1 assembly. The second step involves combining the pMSP3535 + ColE1 assembly with a gfp dropout to form the final Golden Gate compatible vector to be used to create our GABA overexpression plasmid.


Since the original pMSP3535 vector contained two illegal BsaI sites within the ColE1 origin, we sought to replace this ColE1 origin with a BsaI-free one isolated from pYTK001. This assembly process involved linearizing and adding BsmBI sites and compatible overhangs to the pMSP3535 backbone and the pYTK001 ColE1 origin via PCR. After the pMSP3535 backbone and ColE1 origin were successfully amplified by PCR (Fig. 11a), they were joined together using BsmBI assembly. Diagnostic PCR was performed on pMSP3535 + ColE1 minipreps from E. coli transformants to screen for positive samples containing both the pMSP3535 backbone and the ColE1 inserts (Fig. 11b). After confirming the presence of the pMSP3535 vector and ColE1 origin, we partially sequence-confirmed the two miniprep samples.


Figure 11. (A) Agarose gel of successful PCR for the pMSP3535 backbone and the ColE1 origin. Lane 1 contains a negative PCR control. Lanes 2 and 3 contain the ColE1 origin (around 800 bp) and pMSP3535 backbone PCR products (around 4.3 kb). (B) Agarose gel of diagnostic PCR of miniprep samples from pMSP3535 + ColE1 transformants. Lane 1 contains a negative PCR control. Lane 2 contains a positive PCR control for the pMSP3535 backbone, while lanes 3 and 4 contain the pMSP3535 PCR from two miniprep samples. Lane 7 contains a positive PCR control for the ColE1 origin, while lanes 8 and 9 contain the ColE1 PCR from the same two miniprep samples. Evidently, the pMSP3535 backbone and ColE1 origin is present in both tested miniprep samples.


To this pMSP3535 + ColE1 assembly, we wanted to add a gfp dropout part containing internal BsaI sites that will generate overhangs compatible with those in the P8/P32 promoter and M13 terminator part plasmids. Additionally, the incorporation of this gfp dropout part will also allow us to visually screen for positive and negative transformants based on their fluorescence. BsmBI sites and compatible overhangs were added to the gfp dropout part by PCR amplifying it from pYTK047. We have been attempting to linearize and add BsmBI sites and overhangs to the positive pMSP3535 + ColE1 assemblies via PCR, with no success. However, results from diagnostic digests suggested that our assemblies may have contained extra, undesired DNA such as IS elements (Fig. 12). Thus, as of right now, we are screening for more positive pMSP3535 + ColE1 transformants. Once we have trouble-shooted this problem, the pMSP3535 + ColE1 and the gfp dropout PCR products will be joined through BsmBI assembly to form the final Golden Gate compatible pMSP3535 vector.


Figure 12. Agarose gel of pMSP3535 + ColE1 assembly diagnostic digests. Lane 1 contains the undigested plasmid assembly. Lane 2 contains the ClaI-digested plasmid with expected 400 bp and 4.6 kb bands. The actual band generated is apparently above 10 kb. Lane 3 contains the XmnI-digested plasmid with expected 200 bp, 1.5 kb, and 3.3 kb bands. The generated band sizes were 2.5 kb and 4 kb. Lane 4 contains the KpnI-digested assembly with an expected 5.1 kb band. The generated band size was 6 kb. Lane 5 contains the Bg1II-digested assembly with an expected 5.1 kb band. The generated band size was 8 kb.


Assessing erythromycin susceptibility of E. coli


Because we are creating our Golden Gate compatible pMSP3535 shuttle vector in E. coli, we wanted to determine the natural susceptibility of E. coli to erythromycin as the minimum concentration to use has not been established clearly in the literature. Thus, we performed an erythromycin minimum inhibitory concentration test in liquid LB media (Fig. 13). After one-day incubation, we observed that E. coli was resistant up to around 150 µg/mL of erythromycin. From this experiment, we have determined that the optimal erythromycin concentration for selecting against E. coli in liquid culture is around 200-250 µg/mL.


Figure 13. Erythromycin minimum inhibitory concentration tests for E. coli in liquid media. From left to right: 0 µg/mL, 50 µg/mL, 100 µg/mL, 150 µg/mL, 200 µg/mL, 250 µg/mL, 300 µg/mL, 350 µg/mL, and 400 µg/mL.